Hematological Disorder Drugs And Diagnostics Market By Product (Analyzers, Reagents), By End-Users (Academic & Research Institutes, Hospitals, Clinical Laboratories), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: May 24, 2016

Market Segment Insight

 

The global hematological disorder drugs and diagnostics market is segmented on the basis of product type and end-users. On the basis of different product the market is segmented as analyzers and reagents. Hematology analyzers are used for diagnostics like to count blood cells in a blood sample, erythrocyte sedimentation rates (ESRs) tests etc. These analyzers are typically integrated with automation for presentation of results and processing analysis. Automates analyzers play an important role in blood banks and transfusion medicine to screen donors and perform blood quality check. Coagulation analyzers, slide strainers and flow cytometers are few types of analyzers. Hematology reagents are diagnostic instruments used in conjunction with the analyzers. On the basis of different end users the market is segmented as academic and research institutes, hospitals and clinical laboratories.

 

Regional Insight

 

The major regional segments analyzed in the report include North America, Europe, Asia Pacific, and Rest of the World with further bifurcation of them on country level, which includes U.S, Canada, India, China, Japan, Germany, U.K., Spain, Brazil etc. North America has the largest market share of Hematological Disorder Drugs and Diagnostics Market, followed by Europe. The major reason for high market share is increasing geriatric population and increasing blood disorders. For instance, according to the U.S. Census Bureau, approximately 20% of the U.S. population is projected to be 65 years and above by 2030. However, Asia Pacific is growing at a higher CAGR due to large patient base, improving healthcare infrastructure, purchasing power of buyers and increasing government initiatives.


Competitive Insights

 

Some of the key market players are Abbot Laboratories, Amgen, Beckman Coulter, Biogen Idec, Biorad Laboratories, Bristol-Myers Squibb, Eli Lilly And Company, Hemocue Ab, Horbia, Mindray Medical International, Nihon Kohden, Pfizer, Roche Diagnostics A/S, Siemens AG and Sysmex. Expansions, Mergers & acquisition, and collaborations for product development are the key strategies adopted by the market players to sustain in the market. In March 2016 Sysmex Corporation and ClearBridge Biomedics has agreed to jointly develop a new liquid biopsy system. The collaboration will combine ClearBridge BioMedics' in-depth domain knowledge in micro fluidics for the enrichment of rare cells with Sysmex's global leadership in hematology diagnostics, which could lead to a completely new product line in Sysmex's product portfolio of hematology analyzers. Similarly in February 2016, Abbott acquired Alere Inc., making it one step closer in becoming leader in Point-of-Care Testing and significantly increasing its global diagnostics presence.

 

CHAP 1. METHODOLOGY & SCOPE 11
1.1. RESEARCH METHODOLOGY 11
1.2. RESEARCH SCOPE & ASSUMPTIONS 11
1.3. LIST OF DATA SOURCES 11

 

CHAP 2. EXECUTIVE SUMMARY 12
2.1. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET SUMMARY & KEY BUYING CRITERIA 12
2.2. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET OUTLOOK 12
2.3. MARKET SEGMENTATION ANALYSIS 12
2.4. MARKET SIZE AND GROWTH PROSPECTS 2015-2022 12
2.5. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET VALUE CHAIN ANALYSIS 12
2.6. VENDOR LANDSCAPE 12

 

CHAP 3. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET DETERMINENTS 13
3.1. MARKET DRIVER ANALYSIS 13
3.1.1. INCREASING INVESTMENTS IN R&D IN PHARMACEUTICAL SECTOR 13
3.1.2. INCREASING DEMAND OF DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR MANAGEMENT OF BLOOD DISEASES 13
3.1.3. RISING INCIDENCES OF BLOOD RELATED DISORDERS 13
3.2. MARKET RESTRAINT ANALYSIS 13
3.2.1. STRINGENT REGULATION AND INVOLVEMENT OF GOVERNMENT 13
3.2.2. MENIAL ADOPTION IN EMERGING COUNTRIES 13
3.3. KEY OPPORTUNITIES 13
3.3.1. INCREASING USE OF MICROFLUIDICS TECHNOLOGY IN ANALYZERS 13
3.3.2. ADVENT OF FLOW CYTOMETRY TECHNIQUES IN ANALYZERS 13
3.3.3. EVOLUTION OF POINT OF CARE HEMATOLOGY DIAGONISTICS 13
3.4. CHALLENGES 13
3.4.1. HIGH INITIAL COST OF HEMATOLOGY DIAGNOSTIC INSTRUMENTS 13

 

CHAP 4. INDUSTRY ANALYSIS 14
4.1. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET – PORTER’S FIVE FORCE MODEL 14
4.2. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET – PESTEL ANALYSIS 14
4.3. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET – GAP ANALYSIS 14

 

CHAP 5. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY PRODUCT 2015-2022 ($ BILLION) 15
5.1. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY ANALYZERS 2015-2022 ($ BILLION) 15
5.2. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY REAGENTS 2015-2022 ($ BILLION) 15

 

CHAP 6. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY END-USERS 2015-2022 ($ BILLION) 16
6.1. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY ACADEMIC AND RESEARCH INSTITUTES 2015-2022 ($ BILLION) 16
6.2. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY HOSPITALS 2015-2022 ($ BILLION) 16
6.3. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY CLINICAL LABORATORIES 2015-2022 ($ BILLION) 16

 

CHAP 7. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET REGIONAL OUTLOOK 2015-2022 ($ BILLION) 17
7.1. GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY REGION 2015-2022 ($ BILLION) 17
7.2. NORTH AMERICA 17
7.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 17
7.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2015-2022 ($ BILLION) 17
7.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 17
7.2.3.1. U.S. 17
7.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 17
7.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 17
7.2.3.2. CANADA 17
7.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 17
7.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 17
7.3. EUROPE 17
7.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 17
7.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2015-2022 ($ BILLION) 17
7.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 17
7.3.3.1. GERMANY 17
7.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 18
7.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 18
7.3.3.2. UK 18
7.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 18
7.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 18
7.3.3.3. FRANCE 18
7.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 18
7.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 18
7.3.3.4. SPAIN 18
7.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 18
7.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 18
7.3.3.5. REST OF EUROPE 18
7.3.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST2015-2022 ($ BILLION) 18
7.3.3.5.2. RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 18
7.3.3.5.3. OTHER MARKET ESTIMATES AND FORECAST2015-2022 ($ BILLION) 18
7.3.3.5.4. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 19
7.4. ASIA PACIFIC 19
7.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 19
7.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2015-2022 ($ BILLION) 19
7.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 19
7.4.3.1. CHINA 19
7.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 19
7.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 19
7.4.3.2. INDIA 19
7.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 19
7.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 19
7.4.3.3. JAPAN 19
7.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 19
7.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($BILLION) 19
7.4.3.4. OTHERS 19
7.4.3.4.1. OTHER MARKET ESTIMATES AND FORECASTS 2015-2022 ($BILLION) 20
7.4.3.4.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($BILLION) 20
7.5. MIDDLE EAST & AFRICA 20
7.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 20
7.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 20
7.6. LATIN AMERICA 20
7.6.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 20
7.6.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 20
7.6.2.1. BRAZIL 20
7.6.2.1.1. BRAZIL MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 20
7.6.2.1.2. BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 20

 

CHAP 8. COMPETITIVE LANDSCAPE 21
8.1. ABBOT LABORATORIES 22
8.1.1. COMPANY OVERVIEW 22
8.1.2. SCOT ANALYSIS 22
8.1.3. PRODUCT BENCHMARKING 22
8.1.4. STRATEGIC INITIATIVES 22
8.2. AMGEN 22
8.2.1. COMPANY OVERVIEW 22
8.2.2. SCOT ANALYSIS 22
8.2.3. PRODUCT BENCHMARKING 22
8.2.4. STRATEGIC INITIATIVES 22
8.3. BECKMAN COULTER 22
8.3.1. COMPANY OVERVIEW 22
8.3.2. SCOT ANALYSIS 22
8.3.3. PRODUCT BENCHMARKING 22
8.3.4. STRATEGIC INITIATIVES 22
8.4. BIOGEN IDEC 22
8.4.1. COMPANY OVERVIEW 22
8.4.2. SCOT ANALYSIS 22
8.4.3. PRODUCT BENCHMARKING 22
8.4.4. STRATEGIC INITIATIVES 22
8.5. BIORAD LABORATORIES 22
8.5.1. COMPANY OVERVIEW 22
8.5.2. SCOT ANALYSIS 22
8.5.3. PRODUCT BENCHMARKING 22
8.5.4. STRATEGIC INITIATIVES 22
8.6. BRISTOL-MYERS SQUIBB 22
8.6.1. COMPANY OVERVIEW 22
8.6.2. SCOT ANALYSIS 23
8.6.3. PRODUCT BENCHMARKING 23
8.6.4. STRATEGIC INITIATIVES 23
8.7. ELI LILLY AND COMPANY 23
8.7.1. COMPANY OVERVIEW 23
8.7.2. SCOT ANALYSIS 23
8.7.3. PRODUCT BENCHMARKING 23
8.7.4. STRATEGIC INITIATIVES 23
8.8. HEMOCUE AB 23
8.8.1. COMPANY OVERVIEW 23
8.8.2. SCOT ANALYSIS 23
8.8.3. PRODUCT BENCHMARKING 23
8.8.4. STRATEGIC INITIATIVES 23
8.9. HORBIA 23
8.9.1. COMPANY OVERVIEW 23
8.9.2. SCOT ANALYSIS 23
8.9.3. PRODUCT BENCHMARKING 23
8.9.4. STRATEGIC INITIATIVES 23
8.10. MINDRAY MEDICAL INTERNATIONAL 23
8.10.1. COMPANY OVERVIEW 23
8.10.2. SCOT ANALYSIS 23
8.10.3. PRODUCT BENCHMARKING 23
8.10.4. STRATEGIC INITIATIVES 23
8.11. NIHON KOHDEN 23
8.11.1. COMPANY OVERVIEW 23
8.11.2. SCOT ANALYSIS 23
8.11.3. PRODUCT BENCHMARKING 23
8.11.4. STRATEGIC INITIATIVES 24
8.12. PFIZER 24
8.12.1. COMPANY OVERVIEW 24
8.12.2. SCOT ANALYSIS 24
8.12.3. PRODUCT BENCHMARKING 24
8.12.4. STRATEGIC INITIATIVES 24
8.13. ROCHE DIAGNOSTICS A/S 24
8.13.1. COMPANY OVERVIEW 24
8.13.2. SCOT ANALYSIS 24
8.13.3. PRODUCT BENCHMARKING 24
8.13.4. STRATEGIC INITIATIVES 24
8.14. SIEMENS AG 24
8.14.1. COMPANY OVERVIEW 24
8.14.2. SCOT ANALYSIS 24
8.14.3. PRODUCT BENCHMARKING 24
8.14.4. STRATEGIC INITIATIVES 24
8.15. SYSMEX 24
8.15.1. COMPANY OVERVIEW 24
8.15.2. SCOT ANALYSIS 24
8.15.3. PRODUCT BENCHMARKING 24
8.15.4. STRATEGIC INITIATIVES 24

TABLE 1 GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY PRODUCT, 2015-2022 ($ BILLION) 25
TABLE 2 GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY ANALYZERS 2015-2022 ($ BILLION) 25
TABLE 3 GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY REAGENTS 2015-2022 ($ BILLION) 25
TABLE 4 GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY END-USERS, 2015-2022 ($ BILLION) 25
TABLE 5 GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY ACADEMIC AND RESEARCH INSTITUTES 2015-2022 ($ BILLION) 25
TABLE 6 GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY HOSPITALS 2015-2022 ($ BILLION) 25
TABLE 7 GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY CLINICAL LABORATORIES 2015-2022 ($ BILLION) 25
TABLE 8 GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET REGIONAL OUTLOOK 2015-2022 ($ BILLION) 25
TABLE 9 GLOBAL HEMATOLOGICAL DISORDER DRUGS AND DIAGNOSTICS MARKET BY REGION 2015-2022 ($ BILLION) 25
TABLE 10 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 25
TABLE 11 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2015-2022 ($ BILLION) 25
TABLE 12 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 25
TABLE 13 U.S. MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 25
TABLE 14 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 25
TABLE 15 CANADA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 25
TABLE 16 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 26
TABLE 17 EUROPE MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 26
TABLE 18 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2015-2022 ($ BILLION) 26
TABLE 19 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 26
TABLE 20 GERMANY MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 26
TABLE 21 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 26
TABLE 22 UK MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 26
TABLE 23 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 26
TABLE 24 FRANCE MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 26
TABLE 25 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 26
TABLE 26 SPAIN MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 26
TABLE 27 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 26
TABLE 28 RUSSIA MARKET ESTIMATES AND FORECAST2015-2022 ($ BILLION) 26
TABLE 29 RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 26
TABLE 30 OTHER MARKET ESTIMATES AND FORECAST2015-2022 ($ BILLION) 26
TABLE 31 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 26
TABLE 32 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 26
TABLE 33 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2015-2022 ($ BILLION) 27
TABLE 34 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 27
TABLE 35 CHINA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 27
TABLE 36 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 27
TABLE 37 INDIA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 27
TABLE 38 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 27
TABLE 39 JAPAN MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 27
TABLE 40 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($BILLION) 27
TABLE 41 OTHER MARKET ESTIMATES AND FORECASTS 2015-2022 ($ BILLION) 27
TABLE 42 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 27
TABLE 43 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 27
TABLE 44 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 27
TABLE 45 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 27
TABLE 46 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 27
TABLE 47 BRAZIL MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 27
TABLE 48 BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2015-2022 ($ BILLION) 27

FIGURE 1 MARKET SHARE BY REGIONS 28
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 4 EUROPE MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 5 GERMANY MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 8 APAC MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 9 CHINA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 10 INDIA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 11 JAPAN MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 12 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28
FIGURE 13 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2015-2022 ($ BILLION) 28

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)